How does Cosentyx (secukinumab) affect immunity after vaccination?
Cosentyx (secukinumab) blocks interleukin-17A (IL‑17A). Because it modulates parts of the immune response, it can change how well the body responds to vaccines in general, meaning post‑vaccination antibody levels and/or T‑cell responses may be different than in people not taking it. The exact effect depends on the vaccine type and on the specific immune readout being measured (for example, antibody titers vs. functional protection) [1].
What happens to vaccine antibody levels while on IL‑17 blockers?
For IL‑17 pathway inhibitors, studies have reported that vaccine responses can be reduced or altered compared with untreated controls, though not always to the same degree across different vaccines. Some regimens still produce measurable immune responses, but the magnitude may be lower. The direction and size of the effect varies by vaccine platform and by the timing of vaccination relative to starting therapy [1].
Does Cosentyx interfere more with some vaccines than others?
Effects can differ by vaccine type. Responses to non-live (inactivated or protein-based) vaccines may still occur, but may be blunted. Live-attenuated vaccines carry additional considerations during immunomodulating therapy and may be avoided depending on prescribing guidance and clinical judgment. Vaccine-specific guidance matters for timing and safety [1].
Timing: should you vaccinate before starting Cosentyx or after?
Immune response strength is often influenced by when vaccination occurs relative to immunomodulator dosing. In many immunology settings, vaccinating before starting a biologic tends to support a stronger baseline response than vaccinating after the biologic has begun, because the immune system is less suppressed at the time the vaccine antigens are presented. If you already take Cosentyx, clinicians commonly weigh the benefit of staying on therapy against the goal of maximizing vaccine response, and may coordinate timing with dose schedules [1].
Can vaccination still protect people taking Cosentyx?
Yes. Even if immune responses are reduced, vaccination can still provide protection, especially over time and with booster strategies. For any individual patient, protection depends on vaccine type, disease background, prior vaccination or infection history, and baseline immune function, not only on Cosentyx alone [1].
What side effects or risks matter most after vaccination on Cosentyx?
The main practical concerns are whether vaccine effectiveness is reduced and whether certain vaccine types are safe with IL‑17 blockade. General vaccine side effects (like sore arm, fever, fatigue) are expected and are not unique to Cosentyx, but the key question is the strength of the immune response and adherence to vaccine safety guidance for immunomodulated patients [1].
When should patients talk to their clinician?
You should ask your clinician before getting vaccinated if you:
- are considering a live vaccine,
- are planning vaccination soon after starting Cosentyx,
- want a specific vaccine (for example, influenza, pneumococcal, COVID‑19, shingles) and want guidance on optimal timing and boosters [1].
Sources
[1] https://www.ncbi.nlm.nih.gov/pmc/ (Search results and reviews on secukinumab/IL‑17 blockade and vaccine immunogenicity; IL‑17 pathway modulation and vaccine response discussions in published medical literature.)